| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Vireo Growth Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.43 |
| 52 Week High | CA$0.63 |
| 52 Week Low | CA$0.095 |
| Beta | 1.42 |
| 11 Month Change | 16.39% |
| 3 Month Change | 22.41% |
| 1 Year Change | 215.56% |
| 33 Year Change | -71.22% |
| 5 Year Change | -78.04% |
| Change since IPO | -90.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0ZF | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 29.1% | -0.04% | -0.8% |
| 1Y | 215.6% | -20.7% | 2.0% |
Return vs Industry: 0ZF exceeded the German Pharmaceuticals industry which returned -18.9% over the past year.
Return vs Market: 0ZF exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| 0ZF volatility | |
|---|---|
| 0ZF Average Weekly Movement | 15.2% |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0ZF's share price has been volatile over the past 3 months.
Volatility Over Time: 0ZF's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 438 | Josh Rosen | vireohealth.com |
Vireo Growth Inc. operates as a cannabis company in the United States. The company cultivates, manufactures, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York.
Vireo Growth Inc. Fundamentals Summary
| 0ZF fundamental statistics | |
|---|---|
| Market cap | €63.81m |
| Earnings (TTM) | -€21.89m |
| Revenue (TTM) | €85.48m |
0.8x
P/S Ratio-3.1x
P/E RatioIs 0ZF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0ZF income statement (TTM) | |
|---|---|
| Revenue | US$93.13m |
| Cost of Revenue | US$46.30m |
| Gross Profit | US$46.83m |
| Other Expenses | US$70.68m |
| Earnings | -US$23.85m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 50.28% |
| Net Profit Margin | -25.61% |
| Debt/Equity Ratio | -311.4% |
How did 0ZF perform over the long term?
See historical performance and comparison